title: Good correlation between RT-PCR analysis and relapse in Philadelphia (Ph1)-positive acute lymphoblastic leukemia (ALL).
abstract: We sequentially performed cytogenetic analysis and RT-PCR analysis of BCR-ABL transcripts in 17 cases of Ph1-positive ALL who had achieved hematological complete remission (CR) with intensive chemotherapy (CT). Sixteen cases were studied prospectively. All but one of the patients had reached cytogenetic CR, but cytogenetic has low sensitivity in predicting relapse. Twelve patients relapsed, three died in first CR and two were alive in first CR. Two of five, two of four, and five of nine patients who were allografted (in first or second CR), autografted and received consolidation CT, respectively, achieved negative two-round PCR in the bone marrow (BM): three died in CR, three remained in CR with negative two-step PCR in the BM and three relapsed after 22 to 28 months. In all cases, relapse was preceded by switch to PCR positivity in the BM by 4 to 6 months. The remaining nine patients remained PCR-positive in the BM and relapsed after 2 to 16 months. In the four autografted cases, PCR was positive at the time of bone marrow harvest. The two patients who received a purged transplant achieved negative PCR and prolonged CR, whereas the two patients who received an unpurged transplant remained PCR positive and relapsed. In 34% of the samples where analysis was concomitant, sensitivity of PCR proved lower in the blood than in the BM. These findings show that RT-PCR is a useful tool in the monitoring of MRD in Ph1 positive ALL.
authors.affiliation: Laboratoire d'Hématologie A, CHU, Lille, France.
authors.forename: C
authors.initials: C
authors.lastname: Preudhomme
authors.forename: N
authors.initials: N
authors.lastname: Henic
authors.forename: B
authors.initials: B
authors.lastname: Cazin
authors.forename: J L
authors.initials: JL
authors.lastname: Lai
authors.forename: M F
authors.initials: MF
authors.lastname: Bertheas
authors.forename: M
authors.initials: M
authors.lastname: Vanrumbeke
authors.forename: F
authors.initials: F
authors.lastname: Lemoine
authors.forename: J P
authors.initials: JP
authors.lastname: Jouet
authors.forename: E
authors.initials: E
authors.lastname: Deconninck
authors.forename: B
authors.initials: B
authors.lastname: Nelken
authors.forename: A
authors.initials: A
authors.lastname: Cosson
authors.forename: P
authors.initials: P
authors.lastname: Fenaux
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001853:Bone Marrow / Q000473:pathology; D016026:Bone Marrow Transplantation; D002648:Child; D004273:DNA, Neoplasm / Q000235:genetics*; D005500:Follow-Up Studies; D016044:Fusion Proteins, bcr-abl / Q000235:genetics*; D006801:Humans; D009363:Neoplasm Proteins / Q000235:genetics*; D016133:Polymerase Chain Reaction; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000097:blood / Q000235:genetics / Q000401:mortality / Q000473:pathology* / Q000628:therapy; D011237:Predictive Value of Tests; D011379:Prognosis; D011446:Prospective Studies; D012333:RNA, Messenger / Q000032:analysis* / Q000097:blood; D012334:RNA, Neoplasm / Q000032:analysis* / Q000097:blood; D012008:Recurrence; D012680:Sensitivity and Specificity; D017211:Treatment Failure
chemical_list: D004273:DNA, Neoplasm; D009363:Neoplasm Proteins; D012333:RNA, Messenger; D012334:RNA, Neoplasm; D016044:Fusion Proteins, bcr-abl